Ligandal

Ligandal is a private biotechnology and genetic medicine company founded in 2013 by Andre Watson.

The company focuses on precision targeting and non-viral delivery methods for personalized therapies in gene therapy, gene editing, regenerative medicine, immunotherapy, and pandemic defense applications. Ligandal aims to address diseases at their molecular roots through AI-guided precision targeting and advanced delivery technologies. The core of Ligandal's platform is its Peptide Direct Conjugate (PDC) technology, which is enhanced by LigandAI® and Predictive Interactomics®. This technology has been developed over more than a decade to improve the accuracy and efficiency of targeted therapeutic delivery. Ligandal's offerings include gene therapy delivery technologies, gene editing systems for CRISPR-Cas9, regenerative medicine applications, immunotherapy solutions, and pandemic defense programs, including initiatives focused on COVID-19. The company emphasizes cell-specific and tissue-specific targeting, utilizing computational biology and machine learning to design effective delivery strategies.